# Cochrane

# Trusted evidence.

# Informed decisions.

# Library

# Better health.

# Analysis 1.6. Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 6: Induction of clinical remission in UC at longest follow-up: subgroup analysis by age

# Cochrane Database of Systematic Reviews

|Study or Subgroup|FMT Events|FMT Total|Control Events|Control Total|Weight|Risk Ratio M-H, Random, 95% CI|
|---|---|---|---|---|---|---|
|1.6.1 Children|4|13|4|12|9.5%|0.92 [0.29 , 2.89]|
|Subtotal (95% CI)| |13| |12|9.5%|0.92 [0.29 , 2.89]|
|Total events:|4| |4| | | |
|Heterogeneity:|Not applicable|Not applicable|Not applicable|Not applicable|Not applicable|Not applicable|
|Test for overall effect:|Z = 0.14 (P = 0.89)|Z = 0.14 (P = 0.89)|Z = 0.14 (P = 0.89)|Z = 0.14 (P = 0.89)|Z = 0.14 (P = 0.89)|Z = 0.14 (P = 0.89)|
|1.6.2 Adults|12|23|8|22|15.3%|1.43 [0.73 , 2.82]|
|Costello 2019|12|38|3|35|9.2%|3.68 [1.13 , 11.98]|
|Crothers 2021|2|7|0|8|2.3%|5.63 [0.31 , 100.52]|
|Fang 2021|9|10|5|10|15.7%|1.80 [0.94 , 3.46]|
|Haifer 2022|8|15|3|20|9.5%|3.56 [1.13 , 11.18]|
|Moayyedi 2015|9|38|2|37|6.9%|4.38 [1.01 , 18.94]|
|Paramsothy 2017|11|41|3|40|9.0%|3.58 [1.08 , 11.88]|
|Rossen 2015|7|23|5|25|11.1%|1.52 [0.56 , 4.13]|
|Sarbagili Shabat 2022|6|36|6|15|11.5%|0.42 [0.16 , 1.09]|
|Subtotal (95% CI)| |231| |212|90.5%|1.93 [1.17 , 3.17]|
|Total events:|76| |35| | | |
|Heterogeneity:|Tau² = 0.27; Chi² = 16.02, df = 8 (P = 0.04); I² = 50%|Tau² = 0.27; Chi² = 16.02, df = 8 (P = 0.04); I² = 50%|Tau² = 0.27; Chi² = 16.02, df = 8 (P = 0.04); I² = 50%|Tau² = 0.27; Chi² = 16.02, df = 8 (P = 0.04); I² = 50%|Tau² = 0.27; Chi² = 16.02, df = 8 (P = 0.04); I² = 50%|Tau² = 0.27; Chi² = 16.02, df = 8 (P = 0.04); I² = 50%|
|Test for overall effect:|Z = 2.59 (P = 0.010)|Z = 2.59 (P = 0.010)|Z = 2.59 (P = 0.010)|Z = 2.59 (P = 0.010)|Z = 2.59 (P = 0.010)|Z = 2.59 (P = 0.010)|
|Total (95% CI)| |244| |224|100.0%|1.79 [1.13 , 2.84]|
|Total events:|80| |39| | | |
|Heterogeneity:|Tau² = 0.24; Chi² = 17.15, df = 9 (P = 0.05); I² = 48%|Tau² = 0.24; Chi² = 17.15, df = 9 (P = 0.05); I² = 48%|Tau² = 0.24; Chi² = 17.15, df = 9 (P = 0.05); I² = 48%|Tau² = 0.24; Chi² = 17.15, df = 9 (P = 0.05); I² = 48%|Tau² = 0.24; Chi² = 17.15, df = 9 (P = 0.05); I² = 48%|Tau² = 0.24; Chi² = 17.15, df = 9 (P = 0.05); I² = 48%|
|Test for overall effect:|Z = 2.47 (P = 0.01)|Z = 2.47 (P = 0.01)|Z = 2.47 (P = 0.01)|Z = 2.47 (P = 0.01)|Z = 2.47 (P = 0.01)|Z = 2.47 (P = 0.01)|
|Test for subgroup differences:|Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%|Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%|Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%|Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%|Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%|Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%|

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.